CELULARITY - Trademark Details
Status: 700 - Registered
Serial Number
87862993
Registration Number
6102576
Word Mark
CELULARITY
Status
700 - Registered
Status Date
2020-07-14
Filing Date
2018-04-04
Registration Number
6102576
Registration Date
2020-07-14
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2018-11-13
Attorney Name
Law Office Assigned Location Code
M20
Employee Name
FALK, JONATHAN ROBERT
Statements
Goods and Services
Cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, placental tissue for use in scientific, laboratory and medical research; bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; human amniotic membrane and human chorionic membrane for use in scientific, laboratory and medical research; human collagen and extracellular matrix compositions for use in scientific, laboratory and medical research; biological preparations for use in scientific, laboratory and medical research; biological products for use in scientific, laboratory and medical research, namely, placental-derived natural killer cells
Goods and Services
Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, umbilical cord cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological preparations for medical use, namely, for the treatment of cancer and other diseases, namely, auto-immune diseases, inflammatory diseases, Crohn's Disease and Multiple Myeloma; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; cells and biological tissue intended for hair restoration, namely, cells and biological preparations derived from blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen
Goods and Services
Research, development and testing services for others in the fields of genomics, biotechnology and pharmaceuticals; stem cell research services; research, development and testing services in the fields of genomics, biotechnology and pharmaceuticals, namely, collection, testing, processing, preservation, storage and retrieval of cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; laboratory research services in the field of genomics, biotechnology and pharmaceuticals consisting of collection, testing, processing, preservation, storage and retrieval of bioengineered cells, human allograft tissue made from human umbilical cords and human placentas, human amniotic membrane and human chorionic membrane, human collagen and extracellular matrix compositions; providing technical writing and a website featuring information in the field of medical research relating to banking stem cells and cord blood banking; biological research, namely, biosourcing of clinically accessible, immune-tolerant human stem and progenitor and other postpartum placenta-derived cell populations and tissues for medical research; medical research to find methods to restore the structure and function of damaged or diseased tissues and organs, including wound care, reconstructive medicine, whole organ and tissue regeneration and renewal; medical research regarding emergent cell therapies; medical research regarding allogeneic immunotherapy; providing on-line information, news and commentary in the field of medical research relating to the foregoing
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2018-04-12
Primary Code
042
First Use Anywhere Date
2018-02-21
First Use In Commerce Date
2018-02-21
Current Trademark Owners
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Camille M. Miller
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2018-04-07 | NEW APPLICATION ENTERED IN TRAM |
2018-04-12 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2018-07-23 | ASSIGNED TO EXAMINER |
2018-07-24 | NON-FINAL ACTION WRITTEN |
2018-07-24 | NON-FINAL ACTION E-MAILED |
2018-07-24 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2018-08-09 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2018-08-09 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2018-08-09 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2018-08-14 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-08-23 | ASSIGNED TO LIE |
2018-09-11 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
2018-09-13 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
2018-10-02 | NON-FINAL ACTION WRITTEN |
2018-10-02 | NON-FINAL ACTION E-MAILED |
2018-10-02 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2018-10-03 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2018-10-03 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2018-10-03 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2018-10-09 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-10-09 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2018-10-24 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2018-11-13 | PUBLISHED FOR OPPOSITION |
2018-11-13 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2019-01-08 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2019-06-07 | TEAS EXTENSION RECEIVED |
2019-06-07 | EXTENSION 1 FILED |
2019-06-07 | EXTENSION 1 GRANTED |
2019-06-11 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-10-28 | TEAS STATEMENT OF USE RECEIVED |
2019-11-08 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2019-10-28 | USE AMENDMENT FILED |
2019-11-08 | STATEMENT OF USE PROCESSING COMPLETE |
2019-12-04 | SU - NON-FINAL ACTION - WRITTEN |
2019-12-04 | NON-FINAL ACTION E-MAILED |
2019-12-04 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2020-04-28 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2020-04-30 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2020-04-30 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2020-05-22 | SU - FINAL REFUSAL - WRITTEN |
2020-05-22 | FINAL REFUSAL E-MAILED |
2020-05-22 | NOTIFICATION OF FINAL REFUSAL EMAILED |
2020-05-26 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
2020-05-26 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2020-05-26 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2020-06-11 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
2020-06-12 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
2020-07-14 | REGISTERED-PRINCIPAL REGISTER |
2020-10-08 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
2020-10-08 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2020-10-08 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2020-10-08 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2020-10-08 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
2022-01-12 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |